ZEISS HFA3 840

HFA3 provides a streamlined and faster workflow with
an array of new features designed to:

Reduce errors with a single trial lens. Using liquid pressure,
the new Liquid Trial Lens instantly delivers each patient’s
refractive correction with the touch of a button. *Optional Accessory*

Save time with an intuitive new Smart Touch interface that
helps to shorten chair time.

Accelerate clinic flow with equipment that can be learned quickly
and operated easily.

Improve confidence in test results with RelEYE.
Instantly review the patient’s eye position, at any stimulus point.

Gain peace of mind with seamless transfer-ability of legacy data.

Liquid Lens technology: One lens, fewer mistakes
The new automatic Liquid Trial Lens reduces patient setup time by
automatically loading each patient’s refractive correction from
the previous exam.
The result is faster patient flow and reduced chance of
error when selecting a lens during test setup. *Optional Accessory*

SmartTouch interface: Ready, set, test!
The new HFA3 platform gets you up and running with fewer touches.
Simply select the patient’s name and press start, all using an
all-new color graphic user interface.

Exclusive gaze tracking: On track? Know right now
Save time with improved gaze tracking initialization.
Kinetic Perimetry: Significant advancements
Easy to use kinetic graphical user interface with full 180° testing range.

Review quantitative and qualitative information from
all standard HFA analyses, in an easy-to-read format
Change baselines and capture, track and measure
progression simply and easily with Guided
Progression Analysis™ (GPA™)
Use RelEYE to preserve an image of the patient’s
eye at every stimulus presentation during a
SITA™ Standard test
Assess patient’s compliance with RelEYE in both GPA
and single-field analysis modes
Work with either Mean Deviation (MD) or Visual Field
Index™ (VFI™)—or both
Generate HFA reports using a MAC or a PC

The advances in HFA3 from ZEISS only add to the reliable standard that
thousands of practices already depend on for critical diagnoses.
The new model still delivers the interactive analysis you need,
when and where you need it.